ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,671Medicare Part D Prescriptions Filled, Including Refills

Rank: 76 out of 1802

$471K Total Retail Price of All Prescriptions

Rank: 113 out of 1802

332 Patients Receiving at Least One Drug in Part D
83%Patients 65 Years and Older
26% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Wisconsin
Lower avg

Schedule Two
Controlled Substances

5% of this provider’s 332 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

14% of this provider’s 332 patients filled at least one prescription for a schedule three drug, compared to an average of 10%.

Risky Drugs to Seniors

1% of this provider’s 8,127 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

18% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$49 was the average price of a prescription from this provider, compared to $54 among peers.

Prescriptions per Patient

29 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Wisconsin
OMEPRAZOLE 553 428 1 4
LEVOTHYROXINE SODIUM 348 274 2 2
SIMVASTATIN 346 322 3 1
PRAVASTATIN SODIUM 284 214 4 19
FUROSEMIDE 273 257 5 5
AMLODIPINE BESYLATE 260 239 6 6
WARFARIN SODIUM 256 256 7 7
LISINOPRIL 239 212 8 3
LOSARTAN POTASSIUM 185 171 9 18
SERTRALINE HCL 172 140 10 20
ZOLPIDEM TARTRATE 152 124 11 27
TAMSULOSIN HCL 150 136 12 28
POTASSIUM CHLORIDE 144 140 13 15
GLIMEPIRIDE 141 140 14 42
METFORMIN HCL 137 93 15 11
HYDROCODONE-ACETAMINOPHEN 134 112 S3 16 10
METOPROLOL SUCCINATE 133 129 17 13
TRIAMTERENE-HCTZ 127 111 18 49
ATORVASTATIN CALCIUM 121 84 19 14
FENOFIBRATE 119 94 20 56
TRAMADOL HCL 109 102 21 22
DIOVAN 107 76 22 57
PREDNISONE 107 90 22 33
ALLOPURINOL 105 74 24 24
FAMOTIDINE 100 85 25 84
METFORMIN HCL ER 95 80 26 46
DIGOXIN 95 76 26 45
FELODIPINE ER 93 84 28 218
METOPROLOL TARTRATE 92 92 29 9
MELOXICAM 91 71 30 59
ADVAIR DISKUS 83 71 31 32
HYDROCHLOROTHIAZIDE 82 65 32 8
MIRTAZAPINE 80 76 33 38
BENAZEPRIL HCL 79 57 34 61
DONEPEZIL HCL 77 77 35 26
CITALOPRAM HBR 73 69 36 17
ALENDRONATE SODIUM 71 56 37 21
JANUVIA 67 63 38 76
FLUTICASONE PROPIONATE 66 56 39 37
FINASTERIDE 64 59 40 88
PANTOPRAZOLE SODIUM 63 52 41 44
NAMENDA 61 61 42 34
ATENOLOL 61 60 42 12
GABAPENTIN 60 59 44 16
CLOPIDOGREL 55 47 45 48
LOVASTATIN 53 53 46 25
LOSARTAN-HYDROCHLOROTHIAZIDE 52 52 47 52
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Jan. 15, 2010.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.